Chris Murray

This inventor holds 6 USPTO granted patents and 2 published patent applications and 2 EPO patents. Top assignee: Sutro Biopharma, Inc.. Active years: 2017-2025.

USPTO Granted Patents = 6 (Patent Applications = 2)

% Patents Active = 100.0

EPO Patents = 2 (Patent Applications = 4)

Average Co-Inventor Count = 10.0

ph-index = 3

Forward Citations = 14(Granted Patents)

Company Filing History:

6 out of 55

Sutro Biopharma, Inc.

patents

Years Active: 2017-2025

Loading Chart...

6 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12252552 - Modified Fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use (2025-03-18),

2. 11958909 - Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use (2024-04-16),

3. 10669347 - Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use (2020-06-02),

4. 10501558 - Modified Fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use (2019-12-10),

5. 9738724 - Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use (2017-08-22),

6. 9732161 - Modified Fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use (2017-08-15),

Title: Chris Murray: Innovator in Modified Fc Proteins

Introduction

Chris Murray is a prominent inventor based in Soquel, California. He has made significant contributions to the field of biopharmaceuticals, particularly in the development of modified Fc proteins and antibodies. With a total of six patents to his name, Murray's work is at the forefront of therapeutic and diagnostic innovations.

Latest Patents

Murray's latest patents include groundbreaking work on modified Fc proteins that incorporate site-specific non-natural amino acid residues. These proteins are designed for therapeutic and diagnostic applications. The patents detail methods for their preparation and use, highlighting their potential in treatment, prevention, detection, and diagnosis. Additionally, he has developed antibodies that also feature non-natural amino acid residues, further expanding the possibilities for medical applications.

Career Highlights

Chris Murray is currently associated with Sutro Biopharma, Inc., where he continues to push the boundaries of biopharmaceutical research. His innovative approaches have garnered attention in the scientific community, and his patents reflect a commitment to advancing healthcare solutions.

Collaborations

Murray collaborates with notable colleagues, including Christopher D Thanos and Leslie McEvoy. These partnerships enhance the research environment and contribute to the success of their projects.

Conclusion

Chris Murray's contributions to the field of modified Fc proteins and antibodies exemplify the spirit of innovation in biopharmaceuticals. His work not only advances scientific knowledge but also holds promise for improving patient care through novel therapeutic and diagnostic methods.